Hard-to-Heal Bones Could Use a Protein Boost

February 1, 2018/GEN

The occasional bone fracture from a sports injury, motor vehicle accident, or just plain bad luck may seem commonplace in today’s world of advanced medical treatments. Yet, there is always the possibility that the break won’t heal properly or quickly—even with the aid of pins, plates, or a cast. Scientists and physicians have unsuccessfully tried to overcome this potential problem through the administration of bone morphogenetic proteins (BMPs). These regenerative factors were initially designed to promote spinal fusion and bone repair, but studies found that the molecules can over perform, causing excessive or misdirected bone growth.

Now a collaborative team of investigators, led by scientists at the University of Michigan Medical School, have discovered a new molecule they believe will provide the assisted growth to bones that was originally intended using BMPs. Findings from the new study were published today in npj Regenerative Medicine, in an article entitled “Intraoperative Delivery of the Notch Ligand Jagged-1 Regenerates Appendicular and Craniofacial Bone Defects.”

“Each year, 33% of US citizens suffer from a musculoskeletal condition that requires medical intervention, with direct medical costs approaching $1 trillion USD per year,” the researchers write. “Despite the ubiquity of skeletal dysfunction, there are currently limited safe and efficacious bone growth factors in clinical use.”

“Novel therapies have gone underdeveloped because of this assumption that bones heal without problem,” added senior study investigator Kurt Hankenson, D.V.M., Ph.D., a professor of orthopedic surgery at Michigan Medicine. “The reality is there’s a huge number of fractures that occur each year that don’t heal very well.”

Due to the limited number of options for aiding patients with bone healing, the research team began to look for novel approaches. What they attempted was the delivery of additional Jagged-1—a potent osteoinductive protein known to activate the Notch signaling pathway that regulates bone healing—at the spot of a bone injury.

 

READ THE REST HERE

Centric Medical Announces First Quarter Participation at Industry Meetings to Showcase Its Foot & Ankle Portfolio

January 31, 2018

HUNTLEY, Ill.–(BUSINESS WIRE)–Centric Medical, the Foot & Ankle division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology announced today that it will be participating in the 2018 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting which will be held March 6-10 in New Orleans, Louisiana, as well as the 76th Annual 2018 American College of Foot and Ankle Surgeons (ACFAS) Meeting to be held March 22-25 in Nashville, Tennessee. The meetings are expected to attract over 12,000 and 1,800 surgeons, respectfully, with other healthcare professionals from across the globe.

Centric Medical will be promoting the TARSA-LINK® Stand-Alone Wedge Fixation System, the TARSA-LINK® BUNION Stand-Alone Wedge Fixation System, the ROGUE™ Hammertoe Correction System, as well as the newly FDA cleared Foot Plating System and the Cannulated Screw System. In addition, Centric Medical will highlight their Biologics systems, including OSTEO-LINK® 100% Demineralized Bone Matrix and MARROW CELLUTION™ Bone Marrow Harvesting System. Centric Medical’s booth number at AAOS is 714, and booth number at ACFAS is 339.

About Centric Medical

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.centricmedical.com.

Contacts

For Centric Medical
Mr. Omar Faruqi
Chief Financial Officer
ofaruqi@lifespine.com
847-884-6117

Ceterix Announces Completion of Groundbreaking Study of Repair for Meniscal Tears Previously Thought Unrepairable

January 31, 2018

FREMONT, Calif.–(BUSINESS WIRE)–Ceterix® Orthopaedics, Inc., a developer of novel surgical tools that improve a surgeon’s ability to perform minimally invasive orthopaedic procedures, today announced completion of enrollment in STITCH (A Prospective, Non-randomized, Multi-Center Investigation of All-suture-based Repair of Horizontal Meniscal Tears1), the first-ever prospective multicenter investigation of suture-based repair for patients with horizontal meniscus tears, a common type of knee injury.

Because common opinion has held that meniscus repair is not effective for this tear type, horizontal cleavage tears are often treated with meniscectomy – partial removal of the meniscus – despite meniscectomy’s well-established limitations and long-term consequences, including the increased risk of arthritis.In fact, a systemic literature review shows that healing rates for horizontal cleavage tears are comparable to other meniscal tear types that are routinely repaired3, suggesting that more horizontal cleavage tears could be repaired, saving patients the risks of meniscectomy.

The primary objectives of the STITCH study are to assess the success of horizontal meniscus tear repair using Ceterix’s NovoStitch® meniscal repair system or other suture-only techniques, and to assess improvements in knee pain and function after repair. The study targeted enrollment of 30 adults who are 60 and younger at 10 investigational sites in the United States.

“This study aimed to establish the therapeutic value of repair of horizontal tears in multiple practices and across a broad age range,” said orthopaedic surgeon Peter Kurzweil, M.D., principal investigator of the STITCH study. “This study will provide the most credible evidence yet available about this very prevalent and important tear type.”

Arthroscopic surgery is a minimally invasive surgical procedure performed by an orthopaedic surgeon in which a damaged joint is treated, through small incisions with specialized tools, under the guidance of a tiny camera called an arthroscope. Meniscus surgeries are the most common arthroscopic surgery in the United States, with roughly one million procedures annually.

“We are proud to invest in increased understanding of the benefits of our technologies,” said John McCutcheon, president and CEO of Ceterix. “We hope that the results of this study will mean that more patients are spared the potential downsides of meniscectomy through increased use of suture-based repair for these types of tears.”

Ceterix’s NovoStitch meniscal repair system enables surgeons to place stitches arthroscopically in tight joint compartments and thereby address complex knee, hip and shoulder injuries that have not been amenable to repair in the past.

About Ceterix® Orthopaedics

Ceterix® Orthopaedics develops surgical tools that expand and improve what is possible for physicians who treat soft tissue joint injuries such as meniscus tears. Founded in 2010 with the vision of improving outcomes of arthroscopic procedures, Ceterix’s novel meniscal repair system enables surgeons to place suture patterns that were previously only possible in open procedures, or not at all. The NovoStitch Plus meniscal repair system has received 510k clearance in the United States and is indicated for approximation of soft tissue in meniscal repair procedures. The company is based in Fremont, Calif. and is backed by investors Versant Ventures, 5AM Ventures and CRG. For more information, please visit www.ceterix.com.

http://www.clinicaltrials.gov/ct2/show/NCT02237001

Papalia, R. et. al. Meniscectomy as a risk factor for knee osteoarthritis: a systematic review. British Medical Bulletin. 2011; 99:89-106.

Kurzweil, P. et.al. Repair of Horizontal Meniscus Tears: A Systematic Review. Arthroscopy. 2014 Aug 6.

Contacts

for Ceterix Orthopaedics
Sierra Smith, 408-540-4296
sierra@healthandcommerce.com

$3.4 Billion Foot And Ankle Devices Market, 2025

Further Key Findings From the Study Suggest:

  • Bracing and support dominated the market in 2016. Increasing application of braces drives the market and has resulted in industry players developing and introducing new products in the market. For instance, in October 2017, Vickers Grant Holdings, LLC launched ATHLETICA with an ankle brace as an introductory product for the brand.
  • Aging results in significant changes in the skeletal and neuromuscular systems, leading to arthritis, weak ligament, and ACL tear. Symptomatic and asymptomatic tears affect more than 50% of the geriatric population. This is one of the key drivers attributed to the accelerated growth of soft tissue orthopedic devices.
  • Geographically, North America held the largest market share in 2016 and is expected to maintain its position during the forecast period. This large share can be accounted for high adoption rate of new technology and favorable reimbursement scenario.
  • The companies are tending toward providing novel products by adopting new technology. In February 2016, Zimmer Biomet received FDA approval for its 3D printed foot-and-ankle implantUnite3D Bridge Fixation System. The product is perceived to offer greater stability and rigidity due to its integrated structure.
  • Some key industry contributors are DePuy Synthes, Zimmer Biomet, Stryker, Integra LifeSciences Corporation, Wright Medical Technology, Inc., Advanced Orthopedic Solutions, Acumed, Bioretec Ltd., and Ossur.

The global foot and ankle devices market is expected to reach USD 3.4 billion by 2025

The market is expected to observe an exponential growth during the forecast period due to the rising incidence of ankle sprains, hammertoe, bunions, osteoporosis and rheumatoid arthritis.

Ankle fractures are one of the most common types of foot injury. Nearly 170,000 people suffer from ankle fractures per year, which require surgical treatment. It is one of the nine most common fractures. This can be attributed to the relatively small surface area of contact in the ankle and the 1.5 times higher body weight on it at rest & 5.5 times higher forces in case of heavy activity. This makes the long-term viability of ankle joints crucial.

Nearly 50,000 patients are diagnosed with end-stage ankle arthritis per year, wherein the ankle cartilage is worn out, causing painful bone-on-bone contact and disability. These patients are recommended total ankle replacements as opposed to ankle fusion, as it provides higher efficacy, thus driving the market. Favorable reimbursement scenario for joint replacements is one the major contributors to its market growth. Medicare, along with some private insurers, reimburses the procedure.

Key Topics Covered:

Chapter 1 Executive Summary
1.1 Market Snapshot

Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Data Analysis

Chapter 3 Foot And Ankle Devices Market Variables, Trends & Scope
3.1 Market Segmentation and Scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing expenditure on research and development (R&D) by industry players
3.1.1.2 Increasing geriatric population
3.1.1.3 Increasing prevalence of target disease
3.1.1.4 Rising incidence rate of road accidents
3.1.2 Market Restraint Analysis
3.1.2.1 Uncertainty in regulatory reforms
3.1.2.2 High cost of devices
3.2 Penetration & Growth Prospects Mapping
3.3 Foot and Ankle Devices Market – PESTLE Analysis
3.4 Industry Analysis – Porter’s

Chapter 4 Foot And Ankle Devices :Product Estimates & Trend Analysis
4.1 Foot And Ankle Devices Market: Product Movement Analysis
4.2 Bracing and Support
4.3 Joint Implants
4.4 Soft Tissue Orthopedic Devices
4.5 Orthopedic Fixation
4.6 Prosthetics

Chapter 5 Foot And Ankle Devices: Application Estimates & Trend Analysis
5.1 Foot and Ankle Devices Market: Application Movement Analysis
5.2 Hammertoe
5.3 Trauma
5.4 Osteoarthritis
5.5 Rheumatoid Arthritis
5.6 Neurological Disorders
5.7 Bunions
5.8 Osteoporosis

Chapter 6 Foot And Ankle Devices: Regional Estimates & Trend Analysis, by Product and Application

Chapter 7 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/gpnt3k/3_4_bn_foot_and?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Physical Therapy Patients Benefit from In-House Diagnostics

For patients that seek treatment from physical therapists, the prospect of achieving faster and better results when rehabbing from injury or receiving treatment for pain is a no-brainer.

Now, with an increasing number of physical therapy clinics incorporating in-house diagnostics into the practice this is not only possible, but expected.

Armed with more objective results from established tests that include nerve conduction, musculoskeletal ultrasound and other tests, physical therapists are now able to troubleshoot issues with challenging patients much more quickly and accurately in the clinic.

As a result, patients are able to get back to work sooner, return to their beloved sports/exercises and even potentially lead a more pain-free existence without medication.

The traditional approach to PT

In the traditional approach, physical therapists evaluate patients through a physical examination to determine the ideal treatment plan.  However, Physical Therapy physical evaluation tests may miss pathologies and lead to ineffective treatment.

“As physical therapists, a lot of what we do is relatively subjective testing,” explains Nathan Shields, co-owner of Rise Rehabilitation Specialists with 18 years as an orthopedic physical therapist.  “Many of the tests are scientifically proven, but are still based upon the skill level and experience of the therapist.”

In the past, when more sophisticated diagnostic tests were required the patient was typically referred to a small universe of specialists in a process that could take several weeks to receive the results.

Now, however, PTs are regularly bringing this type of testing into the clinic.  This not only requires a significant investment in the equipment, but also training to accurately conduct the tests.

Fortunately, this is being facilitated by national franchise organizations such as Hands-On Diagnostics that help physical therapy practices establish in-house diagnostic services.  To date, the franchise has expanded to 18 different states with over 115 physical therapy facilities.

Among the tests that physical therapists can be trained on include electromyography (EMG), Nerve Conduction Studies (NCS), musculoskeletal and neuro ultrasound, vestibular testing to evaluate patients with vertigo and balance problems and Evoked Potential tests.

EMG/NCS testing is one of the most reliable diagnostic tools for many dysfunctions of the Neuromuscular System.  An EMG measures the electrical activity of muscles at rest and during contraction.  Nerve Conduction Studies (NCS) measure the health of the nerves.

Physical therapists have been able to perform EMG and nerve conduction tests for more than 45 years.  In 1978, the American Physical Therapy Association established a specialty program through the American Board of Physical Therapist Specialties for certification in clinical electrophysiology.

The other diagnostic technique is Musculoskeletal Ultrasound (MSKUS) imaging, which uses sound waves to produce pictures of muscles, tendons, ligaments and joints throughout the body.  It is used to help diagnose sprains, strains, tears, and other soft tissue conditions and to guide therapeutic procedures.

In addition to identifying the severity of the problem, EMG and MSKUS can be used to locate the actual source of pain conditions as well as to monitor ongoing improvement over the course of the physical therapy treatment plan.

Patient Feedback

According to a September 27, 2017 article in Musculoskeletal Care, “Physiotherapists utilizing diagnostic ultrasound in shoulder clinics.  How useful do patients find immediate feedback from the scan as part of the management of their problem?” the utilization of diagnostic ultrasound by physical therapists in patients with shoulder problems concluded that patients highly rated the information gained from ultrasound imaging in a physical therapy environment and felt it assisted them in the understanding, reassurance and management of their problem.

According to the article, to arrive at this conclusion a questionnaire was offered to 103 patients that underwent ultrasound imaging as part of a shoulder assessment over a 6-month period.

According to the article, “Regarding the ability to understand their shoulder problem better and in feeling reassured about their problem, 97% of patients either strongly agreed or agreed that this was the case. Concerning the capability of managing their problem, 89% of patients strongly agreed or agreed that they felt more able to do this. In total, 96% of patients evaluated the ultrasound scan to be of very high/high value to them.”

For Physical Therapist Nathan Shields, perhaps the most important aspect is that patients are experiencing better, faster results.

“We are now able to treat patients with more certainty and, in some cases, we have been able to use the testing to create protocols and get immediate responses on the physical therapy side,” says Shields.

 

For more information, contact Hands-On Diagnostics at (888) 447-6014 or visit www.diagnosticsforpt.com

 

Centric Medical Announces FDA 510(k) Clearance of Foot and Ankle Plating System

January 23, 2018

HUNTLEY, Ill.–(BUSINESS WIRE)–Centric Medical, a division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology announced today the FDA 510(k) clearance of the new Foot and Ankle Plating System. This clearance offers multiple surgical solutions by Centric Medical, to be used in Foot & Ankle reconstruction procedures.

The Centric Medical Foot and Ankle Plating System is comprised of a variety of plates and screws intended to stabilize and fixate bone for a myriad of procedures. The low-profile plates and self-drilling and self-tapping screws were designed to minimize soft tissue disruption and irritation. They are offered in non-sterile, single use implantable components and are provided in a multitude of sizes and shapes which include plates specifically designed for metatarsal phalangeal fusions, lapidus fusions, midfoot fusions and calcaneal slide osteotomies.

“The new Centric Medical Foot and Ankle Plating System is an integral and essential system which adds to a portfolio previously comprised of novel technologies. When paired with our recently FDA cleared Cannulated Screw Internal Fixation System, and our existing OSTEO-LINK® DBM biologics product, we have the potential for excellent clinical outcomes,” said Mariusz Knap, Vice President of Marketing for Life Spine. “As one of the fastest-growing, most innovative companies in our space it is crucial to our surgeons and patients that we continue to advance our offerings.”

About Centric Medical

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.centricmedical.com.

Contacts

For Centric Medical
Mr. Omar Faruqi
Chief Financial Officer
ofaruqi@lifespine.com
847-884-6117

Centric Medical™ Announces FDA 510(k) Clearance of the Cannulated Screw Internal Fixation System for Foot and Ankle Indications

January 16, 2018

HUNTLEY, Ill.–(BUSINESS WIRE)–Centric Medical, a division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology, announced today announced today that the U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance to the Cannulated Screw Internal Fixation System. This clearance further expands the offering of Cannulated Screws for Centric Medical, to be used in Foot & Ankle reconstruction procedures.

“I am excited to add another cannulated screw option to our rapidly growing foot and ankle portfolio. This addition has allowed for a more robust offering for distal extremity procedures including reconstruction, joint fusion, osteotomies, fracture repair, arthrodesis and fracture fixation,” said Mariusz Knap, Vice President of Marketing and Business Development for Life Spine. “The system is extremely easy to use, low profile and offers partially and fully threaded options. I am incredibly proud that Centric Medical saw five 510K clearances in 2017 and I think a full cannulated screw selection is an integral step to a complete foot and ankle portfolio.”

The Cannulated Screw Internal Fixation System is a streamlined multi-component system comprised of titanium alloy, with a wide variety of diameters and lengths. The new options, which are specifically indicated for the forefoot, come in 2.0, 2.5, and 3.0mm diameters with headed and headless designs. This system complements the previously FDA cleared range of 3.5-7.5mm diameters indicated for the midfoot and hindfoot which also offer designs with and without a head.

About Centric Medical

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.centricmedical.com.

Contacts

Centric Medical
Mr. Omar Faruqi
Chief Financial Officer
ofaruqi@lifespine.com
847-884-6117

Catalyst OrthoScience Strengthens Its Board of Directors with The Addition of Greg Rainey

NAPLES, Fla.Jan. 16, 2018 /PRNewswire/ — Catalyst OrthoScience, Inc., a cutting-edge medical device company focused on the upper extremity orthopedics market, today announced the addition of Greg Rainey to its Board of Directors.

Mr. Rainey brings over forty years of experience to the Catalyst OrthoScience Board. Mr. Rainey’s career has been in sales management and business development, serving a cross section of the healthcare industry including orthopedics, medical supplies and equipment, and biologics. Mr. Rainey is the founder and principal of CCI Performance Group, an executive consulting firm designed to deliver sustainable business solutions for both leading Fortune 500 healthcare companies and early-stage medical device ventures. Most recently, he served on the Board of Directors for RTI Surgical (RTIX), and currently sits on the Board of CAS Medical (CASM). Mr. Rainey’s experience includes Stryker Corporation where he served as Vice President of Sales for the Orthopedic Division. Prior to Stryker, Mr. Rainey held sales leadership positions Joint Medical Corporation and U.S. Surgical Corporation.  Mr. Rainey received his undergraduate degree in Biology from Loyola University.

“We are privileged to have Greg join our board at such an important time in our company’s history.  Greg’s successful track record in orthopedics is critical to us as we expand the market presence of our disruptive, stemless shoulder replacement technology. We look forward to his contributions,” said Bob Kaufman, Chairman and Chief Executive Officer of Catalyst OrthoScience.

The Catalyst CSR™ Total Shoulder System provides consistently reproducible shoulder joint restoration with a canal-sparing humeral implant that is smaller, more anatomically-shaped, and less invasive than traditional shoulder replacement

Catalyst OrthoScience was founded in 2014 by orthopedic surgeon Steven Goldberg, M.D. saw the need to make shoulder replacement surgery less invasive and give patients a more normal feeling shoulder after surgery.

About Catalyst OrthoScience Inc.

Headquartered in Naples, FL, Catalyst OrthoScience develops and markets innovative medical device solutions that make orthopedic surgery less invasive and more efficient for both surgeons and patients.

The company’s first offering, the Catalyst CSR™ Total Shoulder System, represents the next evolution in stemless total shoulder arthroplasty. The Catalyst CSR™ is a single-tray total shoulder arthroplasty system containing a non-spherical humeral implant for consistent anatomic joint line restoration and specialized, patented glenoid instrumentation for a less invasive approach that preserves the natural anatomy and removes less of the patient’s bone.  The Catalyst CSR™ System is optimal for use in both the inpatient and outpatient settings and was cleared for use by the FDA in 2016.

Catalyst OrthoScience’s products are marketed under a variety of brands including Catalyst OrthoScience® and Catalyst CSR™. For additional information on the Company, please visit  http://www.catalystortho.com.

 

SOURCE Catalyst OrthoScience, Inc.

Related Links

http://www.catalystortho.com

Hospital for Special Surgery Invests in Sectra Orthopaedic 3D Planning Software for Improved Surgical Outcomes

SHELTON, ConnecticutJanuary 16, 2018 /PRNewswire/ —

International medical imaging IT and cybersecurity company Sectra (STO: SECT-B) announces that Hospital for Special Surgery (HSS), one of the most renowned orthopaedic hospitals in the US, has ordered Sectra’s 3D pre-operative planning solution. The software will provide HSS orthopaedic surgeons with advanced tools to enhance visualization of complex cases with the goal of improving patient outcomes.

“Sectra’s innovative 3D solutions will enable us to make full use of the acquired images, resulting in cutting edge delivery of care to our orthopaedic patients,” says William M. Ricci, MD, Chief of Orthopaedic Trauma Service at HSS. “This 3D platform will improve the quality of pre-operative planning with potential for improved surgical outcomes.”

The 3D pre-operative planning solution includes tools that allow the surgeon to render standard CT images into a three-dimensional interactive image that can be segmented, manipulated, mirrored, templated and 3D printed. The software will integrate with the existing Sectra radiology PACS at HSS to enable surgeons immediate access from anywhere in the hospital.

“This agreement adds software tools for advanced 3D virtual fracture reduction and trauma planning as well as efficient tools for 3D spine planning into the hands of all surgeons at HSS,” says Gustaf Schwang, General Manager Business Unit Orthopaedics at Sectra. “It also includes collaborative development of software, intended to deepen both companies’ leadership position in our respective markets.”

Video: Sectra’s 3D Trauma Pelvic

Sectra at AAOS
Visit Sectra at booth #3967 where the orthopaedic solution will be showcased.

Read more and secure your meeting with Sectra at AAOS.

About Sectra Enterprise Imaging

With more than 25 years of innovation and 1,700 installations, Sectra is a leading global provider of imaging IT solutions that support healthcare in achieving patient-centric care.

The orthopaedic solution is part of Sectra’s complete enterprise imaging offering which is comprised of PACS for imaging-intense departments-radiology, orthopaedics, pathology and cardiology, VNA and Cross Enterprise Workflow solutions. Using the same technical platform, customers can easily extend a departmental solution to create a comprehensive VNA and enterprise image management solution without major investments or the replacement of existing components.

Read more about Sectra and why Sectra PACS is “Best in KLAS” at http://www.sectra.com/medical/.

Contact details:
Andrea Sowitch, Vice President of Marketing
Sectra, Inc.
E-mail: andrea.sowitch@sectra.com
Phone: +1-203-925-0899 ext. 268

Torbjörn Kronander, President and CEO
Sectra AB
E-mail: torbjorn.kronander@sectra.se
Phone: +46-705-23-5227

SOURCE Sectra, Inc

Stimwave Inks $50 Million to Fuel Nationwide Consumer Launch of World’s Only Opioid-Free Pain Management Microchip Stimulator

January 10, 2018

POMPANO BEACH, Fla.–(BUSINESS WIRE)–Stimwave LLC, a medical device manufacturer and independent research institute headquartered in Pompano Beach, Fla., has agreed to over $50 million in additional financing from undisclosed investors to fuel the consumer launch of the world’s first wireless, micro-technology, drug-free neuromodulation device for relief of chronic pain.

Stimwave offers the world’s only wireless micro-sized device cleared by the FDA to treat chronic neuropathic pain throughout the body, from back and leg pain addressed by spinal cord stimulation to peripheral nervous system (PNS) treatment for shoulder pain, wrist and elbow pain, knee pain, hip pain and more, allowing more patients to be treated than ever before with a viable, affordable alternative to help fight opioid usage across the country.

Representing a life-changing technological breakthrough for the more than 400 million people worldwide who endure daily chronic pain, the Stimwave Freedom Stimulators are also the smallest neuromodulation devices available, at a volume size of 0.25 cc compared to the next smallest form factors at 25 cc and greater – 100 times the footprint of Stimwave.

As part of the launch, Stimwave will host a consumer event featuring Cory Everson, six-time Ms. Olympia and world-renowned health and wellness advocate, at the First Annual Medical Conference for Recovery, Regeneration, and the Athlete at the Arnold Classic Sports Festival, taking place March 1, 2018 in Columbus, Ohio.

“The key to Stimwave pain management is the ability to allow the pain sufferer to control their pain wherever and whenever they want,” said Laura Tyler Perryman, Stimwave chairman and co-inventor. “Now patients are in control of how to manage their pain opioid free with wearable and wireless iOS devices, including smart phones and watches. Stimwave is mobile and truly personal, fitting seamlessly into consumer’s lifestyles — whether commuting, playing with kids, or simply relaxing at home. With Stimwave they can take control of their pain.”

The technology, developed by scientists and engineers led by Perryman, uses a tiny injectable microchip device that delivers small pulses of energy to electrodes near surrounding nerves, triggering a reaction that enables the brain to remap specific pain signals, thus providing pain relief.

The Stimwave electroceutical device contains no internal batteries or other toxic materials and can be placed at any peripheral nerve throughout the body or in the spinal column nerve bundles. The Stimwave device is fixed in place by an anchor, so it doesn’t move except with the body’s movement. It naturally stays “in line” with the body’s nerves, allowing a freedom of motion that is impossible with bulkier implanted devices. The Stimwave device is a permanent, long-term implant. The system features the ability to allow the patient to have a whole body 3T or 1.5T MRI without removing the implant, which is unique in the industry.

Please visit www.stimwave.com for more information.

About Stimwave

Stimwave LLC is a privately held medical device company engaged in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management.

Contacts

Glodow Nead Communications
Evan Nicholson, Rosemary O’Brien, Kati Stadum, and Sarah Rogers
415-394-6500
StimwavePR@glodownead.com.